|Bid||1.1800 x 800|
|Ask||1.1900 x 800|
|Day's Range||1.1500 - 1.2200|
|52 Week Range||0.6000 - 1.6800|
|Beta (5Y Monthly)||1.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.50|
It is a pleasure to report that the Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is up 42% in the last quarter. But...
Infinity's (INFI) eganelisib, combined with a checkpoint inhibitor and chemotherapy, gets Fast Track designation by the FDA for the treatment of inoperable locally-advanced or metastatic TNBC in the first-line setting.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eganelisib (IPI-549) in combination with a checkpoint inhibitor and chemotherapy for the treatment of patients with inoperable locally advanced or metastatic triple-negative breast cancer (TNBC), in the first-line setting. Infinity is currently enrolling patients in MARIO-3, the Company’s ongoing Phase 2 study in collaboration with Roche/Genentech to evaluate eganelisib in a novel triple combination front-line regimen with Tecentriq® and Abraxane® in TNBC. Earlier this year Infinity also received Fast Track designation for eganelisib in combination with the checkpoint inhibitor Opdivo® for the treatment of advanced urothelial cancer which the company is studying in MARIO-275, the company’s global, randomized, controlled Phase 2 study in patients with advanced urothelial cancer.